Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy

Eur J Neurol. 2007 Sep;14(9):1060-2. doi: 10.1111/j.1468-1331.2007.01687.x.

Abstract

The efficacy of gabapentin on motor, oculomotor and frontal lobe symptoms was evaluated in patients with progressive supranuclear palsy (PSP) in a pilot study. Fourteen patients were included and seven of them received gabapentin. Clinical evaluation and horizontal eye movement recordings were performed at inclusion and 5-weeks later. Motor score and saccade latency in the visually guided saccade (VGS) task were identical in the two groups. However, the error rate in the antisaccade task was significantly decreased in the gabapentin group. This preliminary study shows that gabapentin improves reflexive saccade inhibition in patients with PSP but does not improve the latency of VGSs.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Amines / therapeutic use*
  • Antiparkinson Agents / therapeutic use*
  • Cyclohexanecarboxylic Acids / therapeutic use*
  • Eye Movements / drug effects*
  • Female
  • Gabapentin
  • Humans
  • Male
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy*
  • Severity of Illness Index
  • Supranuclear Palsy, Progressive / complications
  • Supranuclear Palsy, Progressive / drug therapy*
  • gamma-Aminobutyric Acid / therapeutic use*

Substances

  • Amines
  • Antiparkinson Agents
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin